Skip to content

Omeros OMER Cash & Equivalents

Cash & Equivalents at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$75.08M-2.1%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$5.7M-20.0%
Immunome logo
ImmunomeIMNM
$582.69M+126%
Vor Biopharma logo
Vor BiopharmaVOR
$169.87M+239%
Annexon logo
AnnexonANNX
$175.21M+80.4%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$201M+4.7%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$765.73M+307%
P/S8.5×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's cash & equivalents?
Omeros (OMER) reported cash & equivalents of $1.91M in Q1 2026.
How has Omeros's cash & equivalents changed year-over-year?
Omeros's cash & equivalents decreased by 55.3% year-over-year, from $4.26M to $1.91M.
What is the long-term trend for Omeros's cash & equivalents?
Over 5 years (2020 to 2025), Omeros's cash & equivalents has grown at a -1.7% compound annual growth rate (CAGR), from $10.5M to $9.66M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.